[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1118057T1 - Φαρμακευτικη συνθεση για στοματικη χορηγηση - Google Patents

Φαρμακευτικη συνθεση για στοματικη χορηγηση

Info

Publication number
CY1118057T1
CY1118057T1 CY20161100958T CY161100958T CY1118057T1 CY 1118057 T1 CY1118057 T1 CY 1118057T1 CY 20161100958 T CY20161100958 T CY 20161100958T CY 161100958 T CY161100958 T CY 161100958T CY 1118057 T1 CY1118057 T1 CY 1118057T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
release portion
oral administration
solifenacin
immediate release
Prior art date
Application number
CY20161100958T
Other languages
English (en)
Inventor
Takehiko Yasuji
Noriyuki Kinoshita
Hiroyuki Yoshino
Shuuya Kawahama
Kazuhiro Sako
Akio Sugihara
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1118057T1 publication Critical patent/CY1118057T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μία φαρμακευτική σύνθεση για στοματική χορήγηση η οποία περιλαμβάνει ένα τροποποιημένης αποδέσμευσης τμήμα το οποίο περιέχει ταμσουλοσίνη ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, και ένα άμεσης αποδέσμευσης τμήμα το οποίο περιέχει σολιφενακίνη ή ένα φαρμακευτικώς αποδεκτό άλας αυτής και μία υδρόφιλη ουσία. Στη φαρμακευτική σύνθεση, ο ρυθμός διάλυσης έκαστου φαρμάκου (ειδικότερα, σολιφενακίνης η οποία περιέχεται στο άμεσης αποδέσμευσης τμήμα) είναι παρόμοιος με εκείνον των τωρινών ενός φαρμάκου σκευασμάτων, και το μέγιστο ποσοστό διάλυσης έκαστου φαρμάκου (ειδικότερα, σολιφενακίνης η οποία περιέχεται στο άμεσης αποδέσμευσης τμήμα) είναι 90% ή μεγαλύτερο. Κατά συνέπεια, η φαρμακευτική σύνθεση είναι ένα μοναδικό σκεύασμα (δηλ., ένα συνδυασμένο σκεύασμα) με μια βιοδιαθεσιμότητα ισοδύναμη με εκείνες των τωρινών ενός φαρμάκου σκευασμάτων.
CY20161100958T 2009-02-04 2016-09-27 Φαρμακευτικη συνθεση για στοματικη χορηγηση CY1118057T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14985409P 2009-02-04 2009-02-04
PCT/JP2010/051393 WO2010090172A1 (ja) 2009-02-04 2010-02-02 経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
CY1118057T1 true CY1118057T1 (el) 2017-06-28

Family

ID=42542065

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100958T CY1118057T1 (el) 2009-02-04 2016-09-27 Φαρμακευτικη συνθεση για στοματικη χορηγηση

Country Status (27)

Country Link
US (1) US9198904B2 (el)
EP (1) EP2394648B1 (el)
JP (1) JP5553026B2 (el)
KR (1) KR20110126650A (el)
CN (1) CN102307579B (el)
AU (1) AU2010211725C1 (el)
BR (1) BRPI1007484B1 (el)
CA (1) CA2751039C (el)
CY (1) CY1118057T1 (el)
DK (1) DK2394648T3 (el)
ES (1) ES2603747T3 (el)
HR (1) HRP20161138T1 (el)
HU (1) HUE029638T2 (el)
IL (1) IL214420A (el)
LT (1) LT2394648T (el)
MX (1) MX342062B (el)
MY (1) MY160652A (el)
NZ (1) NZ594311A (el)
PL (1) PL2394648T3 (el)
PT (1) PT2394648T (el)
RS (1) RS55151B1 (el)
RU (1) RU2580652C2 (el)
SG (1) SG173528A1 (el)
SI (1) SI2394648T1 (el)
UA (1) UA102885C2 (el)
WO (1) WO2010090172A1 (el)
ZA (1) ZA201105572B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5028893B2 (ja) 2006-07-18 2012-09-19 日産自動車株式会社 アンダーカバー
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
EP2500013B1 (en) * 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
SG11201501415RA (en) * 2012-08-31 2015-05-28 Astellas Pharma Inc Orally administered medical composition
KR101639692B1 (ko) * 2013-12-13 2016-07-14 제일약품주식회사 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
ES2963886T3 (es) 2017-10-17 2024-04-03 Synthon Bv Comprimidos que contienen tamsulosina y solifenacina
US20230248673A1 (en) * 2020-04-27 2023-08-10 Zim Laboratories Limited Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
PT4255398T (pt) 2020-12-01 2024-10-18 Adamed Pharma S A Preparação administrada oralmente contendo solifenacina e tansulosina

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558156A (en) 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
EP0185117A1 (de) 1984-12-21 1986-06-25 IPEX Getränke-Herstellungs- und Vertriebsgesellschaft mbH Getränk
JPS62114952A (ja) 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
RO112991B1 (ro) 1992-09-18 1998-03-30 Yamanouchi Pharma Co Ltd Preparat tip hidrogel, cu eliberare sustinuta
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6878386B1 (en) * 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
GB0129962D0 (en) 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
AU2003237807B2 (en) 2002-04-15 2008-10-23 Rb Health (Us) Llc Sustained release of guaifenesin combination drugs
CN100355419C (zh) 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US8197846B2 (en) 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
EP1832288B1 (en) * 2004-12-27 2012-06-20 Astellas Pharma Inc. Stable granular pharmaceutical composition of solifenacin or its salt
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
CN101754760A (zh) * 2007-07-20 2010-06-23 安斯泰来制药株式会社 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
AU2010211725A1 (en) 2011-08-25
CA2751039C (en) 2015-05-05
CN102307579B (zh) 2013-10-16
UA102885C2 (ru) 2013-08-27
HUE029638T2 (en) 2017-03-28
AU2010211725B2 (en) 2014-04-10
AU2010211725C1 (en) 2014-10-16
EP2394648A1 (en) 2011-12-14
PT2394648T (pt) 2016-10-03
BRPI1007484A2 (pt) 2016-02-16
US20100233260A1 (en) 2010-09-16
JPWO2010090172A1 (ja) 2012-08-09
CA2751039A1 (en) 2010-08-12
RS55151B1 (sr) 2017-01-31
MX342062B (es) 2016-09-12
JP5553026B2 (ja) 2014-07-16
NZ594311A (en) 2013-05-31
IL214420A0 (en) 2011-09-27
MY160652A (en) 2017-03-15
RU2580652C2 (ru) 2016-04-10
SG173528A1 (en) 2011-09-29
LT2394648T (lt) 2016-10-10
IL214420A (en) 2016-09-29
US9198904B2 (en) 2015-12-01
SI2394648T1 (sl) 2017-02-28
WO2010090172A1 (ja) 2010-08-12
MX2011008188A (es) 2011-09-29
BRPI1007484B1 (pt) 2019-04-16
CN102307579A (zh) 2012-01-04
EP2394648A4 (en) 2012-08-29
DK2394648T3 (en) 2016-09-26
RU2011136636A (ru) 2013-03-10
KR20110126650A (ko) 2011-11-23
ZA201105572B (en) 2012-09-26
EP2394648B1 (en) 2016-08-31
PL2394648T3 (pl) 2016-12-30
HRP20161138T1 (hr) 2016-11-04
ES2603747T3 (es) 2017-03-01

Similar Documents

Publication Publication Date Title
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MY187047A (en) Selective pyy compounds and uses thereof
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
GT201100127A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
CY1116729T1 (el) Τυποποιησεις βασισμενες σε ναλβουφινη και χρησεις αυτων
ATE536172T1 (de) Ezetimibzusammensetzungen
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2023012198A (es) Composiciones de amantadina, preparaciones de estas y metodos de uso.
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
CL2010001174A1 (es) Uso de espironolactona, sus polimorfos, hidratos o solvatos para preparar un medicamento util para prevenir y/o tratar la esclerosis muiltiple.
WO2014119985A3 (es) Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma